News und Analysen
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![LivaNova to Announce Third-Quarter 2023 Results: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN01qRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--21a914cdc6fc0b7ffdd18c2667f61a9a3ee0c178/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LN-Logo-Main-PANTONE.jpg?locale=de)
LivaNova to Announce Third-Quarter 2023 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2023 results on Wednesday, November 1, 2023 at 12 p.m. London time
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Hardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Hardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Convatec Group PLC: Scrip Dividend - Total Issued Shares](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Convatec Group PLC: Scrip Dividend - Total Issued Shares
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Silence Therapeutics to Participate in September Investor Conferences: https://mms.businesswire.com/media/20220126005163/en/1338762/5/Silence-Logo-FINAL-rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1BjVnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--be75b7d9b4c0e9435a1d58c043c3c8d9b8f5a45e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Silence-Logo-FINAL-rgb.jpg?locale=de)
Silence Therapeutics to Participate in September Investor Conferences
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Convatec Group PLC: TR-1 Notification of Major Holdings](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Convatec Group PLC: TR-1 Notification of Major Holdings
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
![Convatec Group PLC: Scrip Dividend – Calculation Price](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Convatec Group PLC: Scrip Dividend – Calculation Price
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
![LivaNova to Present at the Baird Global Healthcare Conference: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN01qRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--21a914cdc6fc0b7ffdd18c2667f61a9a3ee0c178/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LN-Logo-Main-PANTONE.jpg?locale=de)
LivaNova to Present at the Baird Global Healthcare Conference
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present in a fireside chat at
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Silence Therapeutics Reports Second Quarter 2023 Results: https://mms.businesswire.com/media/20220126005163/en/1338762/5/Silence-Logo-FINAL-rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1BjVnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--be75b7d9b4c0e9435a1d58c043c3c8d9b8f5a45e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Silence-Logo-FINAL-rgb.jpg?locale=de)
Silence Therapeutics Reports Second Quarter 2023 Results
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Convatec Group PLC: Company Secretary Change](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)